<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03339115</url>
  </required_header>
  <id_info>
    <org_study_id>CP 17-02</org_study_id>
    <nct_id>NCT03339115</nct_id>
  </id_info>
  <brief_title>AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System</brief_title>
  <acronym>AHEAD</acronym>
  <official_title>European Feasibility Study of High Surgical Risk Patients With Severe Mitral Regurgitation Treated With the Cardiovalve Transfemoral Mitral Valve System (AHEAD Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiovalve Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Meditrial Europe Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Meditrial SrL</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardiovalve Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety of the Cardiovalve Transfemoral Mitral Valve System with&#xD;
      its associated procedure, and observe the device performance in reducing mitral&#xD;
      regurgitation. Data collected in this clinical study will include 30-day safety and&#xD;
      performance, and long-term clinical outcomes over a follow-up of 2 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Cardiovalve offers a mitral replacement valve delivered through a transfemoral access and&#xD;
      transseptal approach, and is intended to reduce mortality and adverse event rates in selected&#xD;
      patients for whom surgical options are not feasible.&#xD;
&#xD;
      Innovation: A truly trans femoral, trans venous delivery of the prosthetic mitral valve which&#xD;
      minimizes procedural risk. The Cardiovalve Implant features a dual nitinol frame for robust&#xD;
      radial strength with decoupling of the atrial flange and ventricular portion which contains&#xD;
      24 grasping legs designed for atraumatic anchoring of the device to the native mitral&#xD;
      annulus. Valve leaflets are made of bovine pericardium. The Cardiovalve implant has a very&#xD;
      low left ventricle (LV) protrusion footprint thus reducing the risk of LV outflow tract&#xD;
      obstruction and/or interference with the LV. The Cardiovalve delivery system (DS) is designed&#xD;
      for transfemoral delivery of the Implant with transseptal access to the left atrium. The&#xD;
      catheter assembly is used to center the implant relative to the native mitral valve plane and&#xD;
      align it with the left ventricual apex-to-base axis. After valve implantation, the delivery&#xD;
      system is withdrawn.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary safety endpoint is freedom from all-cause mortality and major adverse events</measure>
    <time_frame>30 days, 3 Months, 6 Months, 12 Months, and 24 Months</time_frame>
    <description>Freedom from all-cause mortality, all cause hospitalization, major adverse cardiac events (MACE), major device- or procedure- related serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>Intraoperative, 30 Days</time_frame>
    <description>Technical success:&#xD;
I. Absence of procedural mortality&#xD;
II. Delivery and deployment of the device in the correct position and retrieval of delivery catheter, without significant mitral stenosis, LVOT obstruction or paravalvular MR documented by intraoperative imaging [Time Frame:Intraoperative]&#xD;
III. Freedom from emergency surgery or reintervention related to the device or access procedure [Time Frame: 30 days]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>Intraoperative</time_frame>
    <description>I. Absence of procedural mortality or stroke&#xD;
II. Proper placement and positioning of the device&#xD;
III. Freedom from unplanned surgical or interventional procedures related to the device or access procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>30 days, 3 Months, 6 Months, 12 Months, and 24 Months</time_frame>
    <description>IV. Continued intended safety and performance of the device including:&#xD;
No evidence of structural or functional failure&#xD;
No specific device-related technical failure issues and complications&#xD;
Reduction in MR grade to either optimal (0+ to trace) or acceptable (reduced by at least 1 grade from baseline with no more than 2+ MR). Number of patients with reduction in MR grade from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Success</measure>
    <time_frame>30 days, 3 Months, 6 Months, 12 Months, and 24 Months</time_frame>
    <description>I. Device success (either optimal or acceptable) II. Patient returned to the pre-procedural setting&#xD;
III. Freedom from rehospitalizations or reinterventions for the underlying condition (e.g., mitral regurgitation, worsening of heart failure)&#xD;
IV. Improvement from baseline in NYHA functional class Number of patients with improvement in NYHA class&#xD;
V. Six minute walk test Increase in distance (m) from baseline&#xD;
VI. Improvement from baseline in quality-of-life (Kansas City Cardiomyopathy Questionnaire improvement by ≥ 10)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Mitral Regurgitation</condition>
  <condition>Mitral Valve Disease</condition>
  <arm_group>
    <arm_group_label>Cardiovalve Transfemoral Mitral Valve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mitral replacement valve delivered through a transfemoral access and transseptal approach</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiovalve Transfemoral Mitral Valve</intervention_name>
    <description>The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.</description>
    <arm_group_label>Cardiovalve Transfemoral Mitral Valve</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. NYHA functional II, III or ambulatory IV&#xD;
&#xD;
          3. Severe mitral regurgitation (MR grade 3-4+)&#xD;
&#xD;
          4. Subject is on optimal guideline-directed medical therapy for heart failure for at&#xD;
             least 30 days or CRT if indicated.&#xD;
&#xD;
          5. Elevated risk for conventional open mitral valve repair or replacement surgery in the&#xD;
             consideration of the site Heart Team (including a cardiac surgeon, a cardiologist and&#xD;
             imaging specialist as a minimum) based on STS/Euro Score II (per MVARC Part 1),&#xD;
             frailty and co-morbidities.&#xD;
&#xD;
          6. Able to undergo Transesophageal Echocardiography (TEE).&#xD;
&#xD;
          7. Subject understands the study requirements and the treatment procedures and provides&#xD;
             written Informed Consent before any study-specific tests or procedures are performed.&#xD;
&#xD;
          8. The subject commits to return for the scheduled post-operative follow-up visits at the&#xD;
             hospital.&#xD;
&#xD;
             Anatomical Inclusion Criteria&#xD;
&#xD;
          9. Suitable for femoral access procedure and trans septal catheterization&#xD;
&#xD;
         10. Native mitral valve geometry and size and LV outflow tract characteristics compatible&#xD;
             with the Cardiovalve (as assessed by the independent Screening Committee)&#xD;
&#xD;
        Cardiovascular Exclusion Criteria&#xD;
&#xD;
          1. Prior stroke or TIA within 3 months or Modified Rankin Scale ≥4 disability&#xD;
&#xD;
          2. Acute myocardial infarction within the previous 30 days&#xD;
&#xD;
          3. Any prior heart valve surgery or transcatheter mitral intervention&#xD;
&#xD;
          4. Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid&#xD;
             surgery within 30 days&#xD;
&#xD;
          5. Rheumatic heart disease or endocarditis within the previous 3 months&#xD;
&#xD;
          6. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or&#xD;
             any other structural heart disease causing heart failure other than dilated&#xD;
             cardiomyopathy of either ischemic or non-ischemic etiology&#xD;
&#xD;
          7. Existence of inferior vena cava filter or atrial septal device (contraindicating&#xD;
             femoral access and transseptal catheterization)&#xD;
&#xD;
          8. Untreated clinically significant coronary artery disease requiring revascularization&#xD;
&#xD;
          9. Tricuspid valve disease requiring surgery or severe tricuspid regurgitation&#xD;
&#xD;
         10. Aortic or pulmonic valve disease requiring surgery&#xD;
&#xD;
         11. CRT/ICD implant within 30 days&#xD;
&#xD;
             Anatomical Exclusion Criteria (assessed by pre-procedural imaging)&#xD;
&#xD;
         12. Left Ventricular Ejection Fraction (LVEF) &lt;30%&#xD;
&#xD;
         13. LV end diastolic diameter &gt; 70mm&#xD;
&#xD;
         14. Significant abnormalities of the mitral valve and sub-valvular apparatus.&#xD;
&#xD;
         15. Severe mitral annular or leaflets calcification&#xD;
&#xD;
         16. Left atrial or LV thrombus or vegetation&#xD;
&#xD;
         17. Severe right ventricular dysfunction&#xD;
&#xD;
         18. Severe tricuspid or aortic valve disease&#xD;
&#xD;
             General Exclusion Criteria&#xD;
&#xD;
         19. Subject who is currently participating in an investigational study, other than this&#xD;
             study&#xD;
&#xD;
         20. Hemodynamic instability defined as systolic pressure &lt; 90mmHg or the need for&#xD;
             inotropic support or intra-aortic balloon pump or other hemodynamic support device, or&#xD;
             any mechanical heart assistance&#xD;
&#xD;
         21. Subject has contrast agent hypersensitivity that cannot be adequately pre-medicated,&#xD;
             has an allergy to Nitinol alloys (nickel and titanium), or has intolerance to&#xD;
             antiplatelet, anticoagulant, or thrombolytic medications&#xD;
&#xD;
         22. Bleeding diathesis or hypercoagulable state&#xD;
&#xD;
         23. Active peptic ulcer or active gastrointestinal bleeding&#xD;
&#xD;
         24. Pulmonary artery systolic pressure &gt;70 mmHg&#xD;
&#xD;
         25. Patients with renal insufficiency (creatinine &gt; 2.5 mg/dL)&#xD;
&#xD;
         26. Need for emergent or urgent surgery for any reason or any planned cardiac Surgery&#xD;
             within the next 12 months&#xD;
&#xD;
         27. Subject with hepatic insufficiency&#xD;
&#xD;
         28. Subject has a co-morbid illness that may result in a life expectancy of less than one&#xD;
             year&#xD;
&#xD;
         29. Active infection that requires antibiotic therapy&#xD;
&#xD;
         30. Subject is pregnant, breastfeeding or intend to become pregnant within one year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nitza Shoham, VP CA&amp;RA</last_name>
    <role>Study Director</role>
    <affiliation>Cardiovalve Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nitza Shoham, VP CA&amp;A</last_name>
    <phone>+972765388142</phone>
    <email>nitza@cardiovalve.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lauren Beker, PhD</last_name>
    <email>lbaker@boston-biomedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Nickenig, MD</last_name>
      <phone>+4922828715217</phone>
      <email>georg.nickenig@ukbonn.de</email>
    </contact>
    <investigator>
      <last_name>Georg Nickenig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nikos Werner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan-Malte Sinning, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcel Weber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum der Uniklinik Köln</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Baldus, MD</last_name>
      <phone>+49 221 478 32511</phone>
      <email>stephan.baldus@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Baldus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Studienzentrale der Medizinische Klinik II Universitäres Herzzentrum Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Frerker</last_name>
      <phone>0451 500-44501</phone>
      <email>christian.frerker@uksh.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaet_Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan von Bardeleben, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Tobias Ruf, MD</last_name>
      <email>Tobias.Ruf@unimedizin-mainz.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München LMU</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Hausleiter, MD</last_name>
      <phone>+49 89 4400 72361</phone>
      <email>joerg.hausleiter@med.uni-münchen.de</email>
    </contact>
    <investigator>
      <last_name>Jörg Hausleiter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hygea</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantinos Spargias</last_name>
      <email>kspargias@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maria Cecilia Hospital</name>
      <address>
        <city>Cotignola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Colombo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Toscana G. Monasterio-Ospedale del Cuore</name>
      <address>
        <city>Massa</city>
        <zip>54100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Berti, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>Milano</city>
        <zip>20129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Denti, Dr.</last_name>
      <email>denti.paolo@hsr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico San Donato</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Bedogni, MD</last_name>
      <phone>+39 02 5277 4570</phone>
      <email>francesco.bedogni@grupposandonato.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna S Petronio, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 7, 2017</study_first_submitted>
  <study_first_submitted_qc>November 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitral Insufficiency</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Mitral Valve</keyword>
  <keyword>Heart Diseases</keyword>
  <keyword>Valvular Heart Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

